NCT07812480Not yet recruiting
Multimodal Biomarkers in Individual With Cognitive Impairment and Dementia
Multimodal Biomarkers in Individual With Cognitive Impairment and Dementia: A Case Control Study
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
Memory problems can range from normal aging to mild cognitive impairment (MCI) to dementia. This study looks at three ways of measuring what is happening in the brain at each of these stages: a blood test (GFAP), a brain MRI scan, and a brain wave test (EEG). The goal is to see whether combining these three tests can help doctors tell the difference between normal aging, MCI, and dementia more accurately, and whether this approach works well in an Egyptian population, including all common causes of dementia (not only Alzheimer's disease). Adults aged 50 to 85 will be placed into one of three groups: those with normal memory, those with mild memory problems (MCI), and those with dementia. Everyone will have a memory and thinking assessment, a blood draw, a brain MRI, and a brain wave (EEG) recording. No new medication or treatment is given as part of this study; it involves only assessment and testing. The information gathered may help doctors diagnose memory problems earlier and more accurately in the future.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 75 (estimated)
- First submitted
- 1 Sept 2026
- Start date
- 10 Oct 2026
- Primary completion date
- 10 Oct 2028
- Lead sponsor
- Assiut University
- Diseases
- Alzheimer disease
- NCT number
- NCT07812480
What you commit to
- Study type: Observational
- Planned participants: 75
- From 10 Oct 2026 to the primary completion date, 10 Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- age below 50 years .
- other neurological disorders or psychiatric disorders; previous history of stroke; metabolic disturbance; other major medical illnesses; epilepsy; inflammatory, autoimmune, or infectious disease; metallic objects in the body; craniotomy in the past.
- Presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study
- MRI contraindication (pacemaker, metallic implants, severe claustrophobia).
Who the study is looking for
- Dementia diagnosed according to DSM -5\\ with a total Mini-Mental State Examination score \< 24 (or \< 22 according to educational state), together with a Modified Mini-Mental State Examination (3MS) score \< 79 to confirm cognitive impairment.
- Mild cognitive impairment diagnosed according to established diagnostic criteria according to DSM -5.
- Men or women of at least 50 years of age.
- Reliable in individual data and willing to make themselves available for the duration of the study.
- Clear written informed consent obtained from a first-degree relative for each patient participant, and from the control participant himself/herself.
Age in the registry: 50 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.